Pharmacogenomics and health disparities, are we helping?

Abstract

Pharmacogenomics has been at the forefront of precision medicine during the last few decades. Precision medicine carries the potential of improving health outcomes at both the individual as well as population levels. To harness the benefits of its initiatives, careful dissection of existing health disparities as they relate to precision medicine is of paramount importance. Attempting to address the existing disparities at the early stages of design and implementation of these efforts is the only guarantee of a successful just outcome. In this review, we glance at a few determinants of existing health disparities as they intersect with pharmacogenomics research and implementation. In our opinion, highlighting these disparities is imperative for the purpose of researching meaningful solutions. Failing to identify, and hence address, these disparities in the context of the current and future precision medicine initiatives would leave an already strained health system, even more inundated with inequality.

Pharmacogenetics: Using science to reduce racial bias in pain management?

“…SNP analysis and pharmacogenetic‐based opiate prescribing offers a much more precise and biologically driven approach which could reduce the racial and ethnic bias in opiate prescribing practices 12‐16 . Evidence of the impact of different SNP's in opiate drug response is growing.…”

Advancing Precision Medicine in South Tyrol, Italy: A Public Health Development Proposal for a Bilingual, Autonomous Province

“…In pharmacogenomics, the study of how individual genetic variations influence drug responses has led to personalized drug prescriptions, minimizing adverse drug reactions, and improving treatment efficacy. Existing health disparities, as they intersect pharmacogenomic research and implementation, are being identified [ 21 ].…”